PDCD1 and lung cancer: Immune checkpoint blockade (ICB) therapies such as PD-1, PD-L1, and CTLA-4 inhibitors, which are now recognized as a potential treatment strategy, have proven to be extremely effective to prolong the survival time of various advanced tumors like bladder cancer, lung cancer, breast cancer, and cutaneous melanoma (14, 24–26).